Apeiron gains rights to Phase III neuroblastoma candidate

The Children's Cancer Research Institute (Vienna, Austria) and the European Neuroblastoma Research Network (SIOPEN) granted Apeiron Biologics AG (Vienna, Austria) exclusive, worldwide rights to develo...